The newly synthesized inhibitor CM-1 demonstrates the ability to enhance sensitivity of DOT1L R231Q mutant NSCLC cells to EGFR-TKIs and chemotherapy, potentially reversing resistance to these treatments (117). This evidence concerns the gene EGFR and non-small cell lung carcinoma.